Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGNDZ) Other Non-Current Liabilities (2016 - 2025)

Ligand Pharmaceuticals (LGNDZ) has disclosed Other Non-Current Liabilities for 16 consecutive years, with $16.6 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Liabilities fell 44.87% to $16.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $16.6 million through Dec 2025, down 44.87% year-over-year, with the annual reading at $16.6 million for FY2025, 44.87% down from the prior year.
  • Other Non-Current Liabilities hit $16.6 million in Q4 2025 for Ligand Pharmaceuticals, down from $19.9 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $43.7 million in Q3 2023 to a low of $14.2 million in Q1 2025.
  • Historically, Other Non-Current Liabilities has averaged $25.6 million across 5 years, with a median of $27.8 million in 2022.
  • Biggest five-year swings in Other Non-Current Liabilities: soared 98.96% in 2023 and later tumbled 51.04% in 2025.
  • Year by year, Other Non-Current Liabilities stood at $29.6 million in 2021, then decreased by 6.06% to $27.8 million in 2022, then changed by 0.0% to $27.8 million in 2023, then grew by 8.66% to $30.2 million in 2024, then plummeted by 44.87% to $16.6 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for LGNDZ at $16.6 million in Q4 2025, $19.9 million in Q3 2025, and $14.4 million in Q2 2025.